EloraTZP: Results for Lilly's Amylin Plus Tirzepatide Combo
EloraTZP is an investigational once-weekly combination from Eli Lilly that pairs tirzepatide (the medicine in Zepbound and Mounjaro) with eloralintide, an experimental amylin peptide. In a 48-week phase 2 trial presented at the EASD meeting on September 30, 2026, the highest dose led to 23.3% average weight loss in adults with obesity and type 2 diabetes, versus 14.8% with tirzepatide alone. It is not approved, side effects were more common with the combination, and Lilly plans to start phase 3 trials by the end of 2026.
Key facts
- What it is: eloralintide (a selective amylin receptor agonist) plus tirzepatide, given as weekly injections. Investigational, not FDA-approved, as of Oct 2026.
- The trial: phase 2b, 367 adults with obesity or overweight and type 2 diabetes, 48 weeks, presented at EASD 2026 in Milan on Sept 30, 2026.
- Weight loss: 13.2% to 23.3% across the four combination doses, vs 14.8% on tirzepatide 15 mg, 8.2% to 12.3% on eloralintide alone, and 3.0% on placebo.
- Blood sugar: HbA1c fell 2.2 to 2.9 points from a baseline of about 8.1%, vs 2.4 with tirzepatide alone.
- Stopping for side effects: 10.8% to 27.0% on the combination vs 2.9% on tirzepatide alone, mostly gastrointestinal and during dose escalation.
- Next step: Lilly plans phase 3 trials of a co-formulated EloraTZP product by the end of 2026.
What is EloraTZP?
EloraTZP combines two peptide medicines that act on different appetite hormones. Tirzepatide activates both the GLP-1 and GIP receptors and is already FDA-approved for weight management and type 2 diabetes. Eloralintide mimics amylin, a hormone released alongside insulin after meals that is involved in feeling full. Lilly describes eloralintide as a once-weekly, selective amylin receptor agonist.
The idea is the same one behind Novo Nordisk’s CagriSema: pair a GLP-1 medicine with an amylin peptide and see whether the two add up. Our post on CagriSema’s EASD data and FDA timeline covers Novo’s version. If you are new to the idea that these medicines are peptides at all, start with why GLP-1s are peptides.
What did the phase 2 trial find?
The study enrolled 367 adults in the US and Argentina who had obesity or overweight plus type 2 diabetes. Their average starting weight was 105.4 kg and their average HbA1c was 8.1%. People were randomized to placebo, eloralintide alone, tirzepatide 15 mg alone, or one of four combinations (eloralintide 3, 6 or 9 mg with tirzepatide 5, 10 or 15 mg). Doses were raised step by step every 4 weeks.
After 48 weeks:
- Highest combination dose (eloralintide 9 mg with tirzepatide 15 mg): average weight loss of 23.3%, about 24.6 kg (roughly 54 pounds), and an HbA1c drop of 2.9 points.
- Lowest combination dose (eloralintide 3 mg with tirzepatide 5 mg): 13.2% weight loss and a 2.2 point HbA1c drop.
- Tirzepatide 15 mg alone: 14.8% weight loss, HbA1c down 2.4 points.
- Eloralintide alone: 8.2% to 12.3% weight loss, HbA1c down 1.1 to 1.4 points.
- Placebo: 3.0% weight loss, HbA1c down 0.3 points.
Why this matters: people with type 2 diabetes usually lose less weight on GLP-1 medicines than people without it. A result above 20% in this group is notable, and the trial was designed to show what the combination adds over tirzepatide on its own.
Side effects, told plainly
The most common side effects were gastrointestinal, generally mild or moderate, and clustered during the dose escalation period. They were more frequent with the combination than with either medicine alone. The share of people who stopped treatment because of side effects ranged from 10.8% to 27.0% in the combination groups, compared with 0% to 10.8% on eloralintide alone, 2.9% on tirzepatide alone and 16.7% on placebo, as reported by HCPLive.
That gap is the main caveat. Lilly says phase 3 will use an optimized escalation schedule, which is meant to make the start of treatment easier to tolerate. Whether it does is something the next trials will need to show.
Other honest limits
- These are phase 2 results from one trial of 367 people. Phase 2 trials are built to choose doses, not to prove a medicine works and is safe for approval.
- The results were released by Lilly and presented at a conference on September 30, 2026; a peer-reviewed journal paper had not been reported as of Oct 6, 2026.
- The trial only included people with type 2 diabetes. Results may differ for people without diabetes.
- Comparisons with other drugs from different trials are not head to head. For context on the main obesity trials, see retatrutide vs tirzepatide vs semaglutide.
When could EloraTZP be available?
Not soon. Lilly plans to begin phase 3 trials of a single co-formulated EloraTZP product by the end of 2026, and phase 3 trials of eloralintide on its own are already under way. Phase 3 programs usually take years before a filing. Until then, eloralintide and EloraTZP can only be received inside a clinical trial. Anything sold online under those names is not an approved product, and there is no legal compounded version. For how unapproved peptides are treated today, see our legal status tracker.
What it means for you
EloraTZP is good news for people living with obesity and type 2 diabetes: an amylin peptide added to an approved medicine produced more weight loss and similar or better blood sugar control than tirzepatide alone. It is early, investigational and harder to tolerate in this trial. Tirzepatide itself is approved today, and a licensed provider can talk through whether it or another approved option fits. Our GLP-1 price tracker and semaglutide vs tirzepatide guide can help you prepare for that conversation.
Sources
- EurekAlert (EASD 2026): EloraTZP led to weight loss of up to 23.3% in people with obesity and type 2 diabetes (Sept 30, 2026)
- HCPLive: EASD 2026, EloraTZP bests tirzepatide on weight loss and A1C in type 2 diabetes (Sept 30, 2026)
- Clinical Trials Arena: Lilly’s amylin-tirzepatide combo beats its weight loss drug alone (2026)
- Eli Lilly: new data on Foundayo, retatrutide and eloraTZP at EASD 2026
- BioPharma Dive: 3 takeaways from a European obesity scientific meeting (Oct 2026)
Educational content only, not medical advice. Talk to a licensed provider about whether any medicine is right for you.